LifeScience Clinical & Diagnostic
Ferronova’s Nanoparticle Platform Shows Promise for More Precise Gastric and Oesophageal Cancer Surgery
Australian medical technology company Ferronova has announced preliminary findings from the MAGMAP multi-centre trial involving 62 gastric and oesopha...
September 16, 2026 | News
Takeda’s Zasocitinib Receives US FDA Priority Review for Plaque Psoriasis
-Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for za...
September 16, 2026 | News
IonOpticks Launches Aurora Series 5 to Boost Robustness in High-Throughput Proteomics
New CoreJet™ integrated emitter technology and a redesigned nanoZero® union combine proven Aurora Series® performance with a step-change in r...
September 15, 2026 | News
US FDA Approves Telix’s Pixclara as First FET-PET Imaging Drug for Brain Cancer
Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). Approval addresses a significant unmet need, helping physicians ...
September 15, 2026 | News
Accro Bioscience’s AC-101 Enters China’s Rare Disease Innovative Drug Pilot Programme for Blau Syndrome
Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring...
September 15, 2026 | News
Bausch + Lomb Secures European CE Mark for Next-Generation SeeLyra Femtosecond Laser
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, announced European C...
September 14, 2026 | News
Exegenesis Bio, Modalis Partner to Advance CRISPR-Based DMD Therapy MDL-201
Exegenesis Bio and Modalis Therapeutics Corporation (TOKYO: 4883; "Modalis") announced that they have signed a research collaboration and license agr...
September 14, 2026 | News
Gan&Lee Doses First Participant in Phase I Trial of Once-Weekly Oral GLP-1 Candidate GZC8072
Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH...
September 11, 2026 | News
Ascletis Begins US Phase I Trial of Oral Amylin Agonist ASC36 for Obesity
- This trial marks the fourth Phase I peptide study for Ascletis this year. - ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at ste...
September 10, 2026 | News
CorrectSequence’s Base-Editing Therapy Shows Durable Response Across Diverse β-Hemoglobinopathy Patients
Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT pati...
September 09, 2026 | News
Dimerix Secures A$34M Non-Dilutive Funding to Advance Kidney Disease Pipeline Subheadline:
Dimerix successfully enters into non-dilutive facility agreements to access A$34 million[1] with a syndicate of Australian and U.S. independent lend...
September 07, 2026 | News
Akeso’s Ivonescimab Shows Significant Overall Survival Benefit Over Pembrolizumab in Phase III NSCLC Trial
Akeso, Inc. announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Dat...
September 04, 2026 | News
Norroy Bioscience Secures China Clearance for Phase III Trial of PSMA-Targeted Radiopharmaceutical
NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that it has received regu...
September 04, 2026 | News
Alteogen, Novartis Ink Up to $3.2B Deal for Subcutaneous Biologics Using ALT-B4
Novartis obtains rights to develop and commercialize subcutaneous formulations for multiple products utilizing ALT-B4 Alteogen's fourth licensing agreem...
September 04, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
